Nahdi Medical Company Share Price

Equities

4164

SA15HG521213

Drug Retailers

End-of-day quote Saudi Arabian S.E. 23:00:00 24/04/2024 BST 5-day change 1st Jan Change
135.8 SAR -0.15% Intraday chart for Nahdi Medical Company -3.14% -0.88%

Financials

Sales 2024 * 9.11B 2.43B 195B Sales 2025 * 9.57B 2.55B 205B Capitalization 17.65B 4.71B 377B
Net income 2024 * 893M 238M 19.09B Net income 2025 * 961M 256M 20.54B EV / Sales 2024 * 1.97 x
Net Debt 2024 * 269M 71.85M 5.76B Net Debt 2025 * 142M 37.86M 3.03B EV / Sales 2025 * 1.86 x
P/E ratio 2024 *
19.8 x
P/E ratio 2025 *
18.4 x
Employees 6,182
Yield 2024 *
3.98%
Yield 2025 *
4.36%
Free-Float 40%
More Fundamentals * Assessed data
Dynamic Chart
Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nahdi Medical Posts Higher FY23 Net Profit, Revenue MT
Nahdi Medical Company Approves Cash Dividend Distribution for the Second Half of 2023 CI
Nahdi Medical Company Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
OptiBiotix says market still "volatile" but partner sales improving AN
Saudi Arabia healthcare group Fakeeh Care weighs IPO, appoints HSBC - sources RE
Nahdi Medical Company Reports Earnings Results for the Second Quarter Ended June 30, 2023 CI
Nahdi Medical Company Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nahdi Medical Company Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nahdi Medical Company Reports Earnings Results for the Third Quarter Ended September 30, 2022 CI
Nahdi Medical Company Reports Earnings Results for the Third Quarter Ended September 30, 2022 CI
OptiBiotix Health gets approval to sell products in Saudi Arabia AN
OptiBiotix Health Plc Announces Exclusive Distributor Nahdi Medical Co Has Received Approval from the Saudi Food and Drug Authority for GoFigure Shakes and Bars Containing Patented Weight Management Aid Slimbiome CI
Nahdi Medical Company Announces the Establishment of a New Company, Owned by its Subsidiaries CI
Certain Ordinary Shares of Nahdi Medical Company are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
More news
1 day-0.15%
1 week-3.14%
Current month-7.62%
1 month-11.36%
3 months-5.56%
6 months-2.30%
Current year-0.88%
More quotes
1 week
134.60
Extreme 134.6
142.60
1 month
134.60
Extreme 134.6
152.00
Current year
134.60
Extreme 134.6
156.80
1 year
129.00
Extreme 129
183.40
3 years
129.00
Extreme 129
209.40
5 years
129.00
Extreme 129
209.40
10 years
129.00
Extreme 129
209.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 31/12/13
Founder 62 17/06/86
Director of Finance/CFO 50 31/12/12
Members of the board TitleAgeSince
Chairman 73 31/12/20
Director/Board Member 71 31/12/20
Director/Board Member 45 31/12/20
More insiders
Date Price Change Volume
25/04/24 135.8 -0.15% 322,264
24/04/24 136 -0.73% 335,274
23/04/24 137 -2.14% 357,868
22/04/24 140 -1.27% 355,879
21/04/24 141.8 +1.14% 261,096

End-of-day quote Saudi Arabian S.E., April 24, 2024

More quotes
Al Nahdi Medical Company SJSC is a Saudi Arabia-based retail pharmacy and healthcare company. The Company is engaged in the wholesale and retail trading of cosmetics, pharmaceutical products, special and healthy foods and medical equipment. The Company operates two operating segments: Front Shop and Pharma. The Company provides medicine, wellness, mom & baby, beauty and other wide-ranging FMCG products. The Company provides omni-health services through its polyclinics, express clinics, telemedicine, labs, and home healthcare. The Company operates approximately 1,150 stores in 144 cities and towns in the Kingdom of Saudi Arabia and the United Arab Emirates. The Company’s subsidiaries include Al Nahdi Care, Sakhaa Golden Company, and Nahdi Investment Company.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
135.8 SAR
Average target price
155.4 SAR
Spread / Average Target
+14.46%
Consensus